PECULARITIES OF DEVELOPMENT OF REASSORTANT STRAINS FOR LIVE INFLUENZA VACCINE BASED ON VIRUSES WITH PANDEMIC POTENTIAL



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective of the research: to characterize the effectiveness of obtaining reassortant strains for live influenza vaccine based on pandemic and potentially pandemic influenza viruses which are new for humans. Materials and methods of the research: influenza virus A(H1N1)pdm09, potentially pandemic A(H3N2)v and A(H5N1) influenza viruses, a master donor virus for the Russian live influenza vaccine. Virological and molecular genetics methods of research. Results: strains with a 6:2 genome composition for live influenza reassortant vaccine based on the pandemic '(H1N1)pdm09 virus and swine influenza A(H3N2)v virus have been successfully obtained. The reassortment of highly pathogenic avian influenza (HPAI) viruses A(H5N1) and human A(H2N2) master donor virus for live attenuated influenza vaccine is complicated by the features of the constellation of their genes. H5N2 reassortants which inherited only HA gene from HPAI viruses of avian influenza were obtained. Despite the impossibility of development of 6:2 reassortants, the phenotypic, preclinical characteristics of the reassortants with the 7:1 genome composition, and their further clinical studies on volunteers have shown that such vaccine strains can be successfully used to prevent diseases caused by avian influenza viruses. Conclusion. When vaccine strains against potentially pandemic influenza viruses are obtained by the classical reassortment technique then the success depends on the mutual constellation of genes of phylogenetically distant far apart parental viruses. In some cases the inheritance by the reassortant of a single HA gene from the antigenic actual virus can be a compromise for LAIV development.

Full Text

Restricted Access

About the authors

N V Larionova

FSBSI «Institute of Experimental Medicine»

I V Kiseleva

FSBSI «Institute of Experimental Medicine»

E M Doroshenko

FSBSI «Institute of Experimental Medicine»

L G Rudenko

FSBSI «Institute of Experimental Medicine»

References

  1. Александрова Г.И. Применение метода генетической рекомбинации для получения вакцинных штаммов вируса гриппа // Вопр. вирусол. 1977. № 4. С. 387-395. [Alexandrova G.I. Application of the genetic recombination method to obtain vaccine strains of the influenza virus. Vopr. virusol., 1977, No 4, рр. 387-395].
  2. Руденко Л.Г, Ларионова Н.В., Киселева И.В., Исакова-Сивак И.Н. Живая гриппозная вакцина, итоги разработок и перспективы применения // Медицинский академический журнал. 2010. № 10 (4). С. 235-239. [Rudenko L.G., Larionova N.V., Kiseleva I.V., Isakova-Sivak I.N. Live influenza vaccine, the results of development and the prospects for use. Medical Academic Journal, 2010, No 10 (4), рр. 235-239].
  3. Александрова Г.И., Климов А.И. Живая вакцина против гриппа. СПб.: Наука, 1994. 152 с. [Alexandrova G.I., Klimov A.I. Live vaccine against influenza. St. Petersburg: Science, 1994, 152 p.].
  4. WHO. Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development [Электронный ресурс]. Режим доступа: http://www.who.int/csr/resources/publications/swineflu/vaccine_recommendations/en/index.html.
  5. Centers for Disease Control and Prevention (CDC). Influenza A (H3N2) variant virus. [Электронный ресурс]. Режим доступа: http://www.cdc.gov/flu/swineflu/h3n2v-cases.htm.
  6. WHO. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2018 [Электронный ресурс] // March, 2. 2018. Режим доступа: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/.
  7. WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness [Электронный ресурс] // Sept. 2015. Режим доступа: http://www.who.int/influenza/vaccines/virus/201509_zoonotic_vaccinevirusupdate.pdf?ua=1.
  8. Rudneva I.A., Timofeeva T.A., Shilov A.A., Kochergin-Nikitsky K.S., Varich N.L., Ilyushina N.A., Gambaryan A.S., Krylov P.S., Kaverin N.V. Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants // Arch Virol. 2007. Vol. 152 (6). Р. 1139-1145.
  9. Методы определения показателей качества иммунобиологических препаратов для профилактики и диагностики гриппа. МУ 3.3.2.1758-03 (утв. главным государственным санитарным врачом РФ) [Электронный ресурс] 28.09.2003. Режим доступа: // http://docs.cntd.ru/document/1200040123.[MU 3.3.2.1758-03 Methods for determining the quality of immunobiological drugs for the prevention and diagnosis of influenza [Electronic resource] // 28.09.2003. Access mode: http://docs.cntd.ru/document/1200040123].
  10. Киселева И.В., Voeten J.T.M., Teley L.C.P., Ларионова Н.В., Дубровина И.А., Бердыгулова Ж.А., Баженова Е.А., van denBosch H., Heldens J.G.M., Руденко Л.Г. Анализ состава генома штаммов сезонной и пандемической живой гриппозной вакцины // Молекулярная генетика, микробиология и вирусология. 2011. № 4. С. 29-36. [Kiseleva I.V., Voeten J.T.M., Teley L.C.P., Larionova N.V., Dubrovina I.A., Berdygulova Zh.A., Bazhenova E.A., van denBosch H., Heldens J.G.M., Rudenko L.G. Analysis of the genome composition of seasonal and pandemic live influenza vaccine strains. Molecular genetics, microbiology and virology, 2011, No 4, рр. 29-36].
  11. План мероприятий на 2009 год по предупреждению распространения в Российской Федерации заболеваний, вызванных высокопатогенным вирусом гриппа. Утвержден распоряжением Правительства Российской Федерации № 1098. [Электронный ресурс] // 23.08.2010 г. Режим доступа: http://sbornik-zakonov.ru/38169.html. [Plan of measures for 2009 to prevent the spread of diseases caused by highly pathogenic influenza virus in the Russian Federation. Approved by the decree of the Government of the RF No. 1098. [Electronic resource] // 23.08.2010. Access mode: http://sbornik-zakonov.ru/38169.html].
  12. Kiseleva I., Larionova N., Kuznetsov V., Rudenko L. Phenotypic characteristics of novel swine-origin influenza A/California/07/2009 (H1N1) virus // Influenza and Other Respiratory Viruses. 2009. Vol. 4 (1). Р. 1-5.
  13. Ларионова Н.В., Киселева И.В., Миронов А.Н., Бушменков Д.С., Донина С.А., Петухова Г.Д., Кореньков Д.А., Найхин А.Н., Руденко Л.Г. Живая гриппозная вакцина из реассортантного штамма A/17/Калифорния/2009/38 (H1N1) эффективный препарат для профилактики пандемического гриппа // Медицинский академический журнал. 2011. № 11 (4). С. 3-12. [Larionova N.V., Kiseleva I.V., Mironov A.N., Bushmenkov D.S., Donina S.A., Petukhova G.D., Korenkov D.A., Naihin A.N., Rudenko L.G. Live influenza vaccine from the reassortant strain A/17/California/2009/38 (H1N1) an effective drug for the prevention of pandemic influenza. Medical Academic Journal, 2011, No 11 (4), рр. 3-12].
  14. Stittelaar K.J., Kroeze E.J.B.V., de Waal L., van Amerongen G., van den Brand J.M.A., Simon J.H., Kiseleva I., Larionova N., Rudenko L., Dhere R., Thirapakpoomanunt S., Kieny M.P., Osterhaus A.D.M.E. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets // Vaccine. 2011. Vol. 29 (49). Р. 9265-9270.
  15. Larionova N., Kiseleva I., Isakova-Sivak I., Rekstin A., Dubrovina I., Bazhenova E., Ross T.M., Swayne D., Gubareva L., Tsvetnitsky V., Fedorova E., Doroshenko E., Rudenko L. Live attenuated influenza vaccines against highly pathogenic H5N1 avian influenza: development and preclinical characterization // J. Vaccines and Vaccination. 2013. Vol. 4 (8). P. 1-11. doi: 10.4172/2157-7560.1000208.
  16. Rudenko L., Kiseleva I., Stukova M., Erofeeva M., Naykhin A., Donina S., Larionova N., Pisareva M., Krivitskaya V., Flores J., Dubrovina I., Isakova-Sivak I., Petukhova G., Bazhenova E., Smolonogina T., Kuznetsova V., Nikiforova A., Kiselev O., Power M., Tsvetnitsky V., Victor J.C., Neuzil K.M. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study // Vaccine. 2015. Vol. 33 (39). Р. 5110-5117.
  17. Gambaryan A.S., Lomakina N.F., Boravleva E.Y., Kropotkina E.A., Mashin V.V., Krasilnikov I.V., Klimov A.I., Rudenko L.G. Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine) // Influ Respi Viruses. 2012. Vol. 6 (3). Р. 188-195.
  18. Desheva J.A., Rudenko L.G., Alexandrova G.I., Lu X., Rekstin A.R., Katz J., Cox N., Klimov A.I. Reassortment between avian apathogenic and human attenuated cold-adapted viruses as an approach for preparing influenza pandemic vaccines // Proceedings of Options for the Control of Influenza V, International Congress Series, 1263. Elsevier, Amsterdam. 2004. Р. 724-727.
  19. Bazhenova E., Kiseleva I., Isakova-Sivak I., Kotomina T. Two alternative approaches to generate live attenuated influenza vaccine candidates against potentially pandemic avian influenza H7N9 virus // Biomed. J. Sci & Tech Res. 2018. Vol. 3 (4). P. 1-3. doi: 10.26717/BJSTR.2018.03.000925.
  20. Isakova-Sivak I., Rudenko L. Tackling a novel lethal virus: a focus on H7N9 vaccine development // J. Expert Review of Vaccines. 2017. Vol. 16 (7). P. 709-721.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Larionova N.V., Kiseleva I.V., Doroshenko E.M., Rudenko L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies